Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Risankizumab-rzaa (Skyrizi(®); AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Vidhatha, Yang, Eric J, Myers, Bridget, Liao, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985981/
https://www.ncbi.nlm.nih.gov/pubmed/32158251
http://dx.doi.org/10.2147/JIR.S215196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985981/
https://www.ncbi.nlm.nih.gov/pubmed/32158251
http://dx.doi.org/10.2147/JIR.S215196

Ejemplares similares